The FDA plans to crackdown on alternative remedies; Senator Lamar Alexander, R-Tennessee, says his Obamacare insurer fix will be in the government funding bill; Alabama prepares to drop coverage for 7000 children.
The FDA plans to begin targeting homeopathic medicines that are unproven and pose safety risks. According to AP, the new framework would still leave the majority of products, considered low-risk, on the market. Currently, the FDA does not review safety or effectiveness of homeopathic products and some have recently been the source of major safety problems, such as teething tablets that were tied to seizures and deaths in infants and children. The agency is taking comments for 90 days before it finalizes its plan.
A bipartisan measure that would stabilize Affordable Care Act (ACA) insurer markets is expected to be included in the government funding bill. The bill has to pass by Friday, December 22, to avert a government shutdown, but the inclusion of the ACA fix may set up a showdown with conservatives, reported The Hill. Senate Majority Leader Mitch McConnell, R-Kentucky, pledged to Senator Susan Collins, R-Maine, that he would support passage of the ACA fix in exchange for her vote on the GOP tax bill, and McConnell also told Senator Lamar Alexander, R-Tennessee, that there would be action on the bipartisan measure before the end of the year.
With no new funding for the Children’s Health Insurance Program (CHIP), Alabama has become the first state to announce it is cutting coverage. Kaiser Health News reported Alabama will drop coverage for 7000 kids on January 1, 2018, and will freeze enrollment. If Congress doesn’t act, then the state will close CHIP entirely on February 1, 2018. Other states, including Colorado and Virginia, have begun informing parents that their CHIP programs may also be cut. The director of Alabama’s CHIP program estimates that fewer than 10% of CHIP enrollees will be able to qualify for Medicaid.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More